Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians

Overview

Journal J Transplant

Publisher Wiley

Specialty General Surgery

Date 2018 Aug 30

PMID 30155279

Citations 16

Authors

Muhammad Abdul Mabood Khalil

Muhammad Ashhad Ullah Khalil

Taqi F Taufeeq Khan

Jackson Tan

Affiliations

Soon will be listed here.

Abstract

Drug-induced hematological cytopenia is common in kidney transplantation. Various cytopenia including leucopenia (neutropenia), thrombocytopenia, and anemia can occur in kidney transplant recipients. Persistent severe leucopenia or neutropenia can lead to opportunistic infections of various etiologies. On the contrary, reducing or stopping immunosuppressive medications in these events can provoke a rejection. Transplant clinicians are often faced with the delicate dilemma of balancing cytopenia and rejection from adjustments of immunosuppressive regimen. Differentials of drug-induced cytopenia are wide. Identification of culprit medication and subsequent modification is also challenging. In this review, we will discuss individual drug implicated in causing cytopenia and correlate it with corresponding literature evidence.

Citing Articles

Early Steroid Withdrawal in Kidney Transplant Recipients: CON.

Aziz F, Parajuli S Kidney360. 2025; 6(2):187-190.

PMID: 40014438 PMC: 11882248. DOI: 10.34067/KID.0000000000000323.

Tacrolimus- and Mycophenolate-Mediated Toxicity: Clinical Considerations and Options in Management of Post-Transplant Patients.

Kaye A, Shah S, Johnson C, De Witt A, Thomassen A, Daniel C Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852117 PMC: 11763814. DOI: 10.3390/cimb47010002.

Current and emerging tools for simultaneous assessment of infection and rejection risk in transplantation.

Tharmaraj D, Mulley W, Dendle C Front Immunol. 2024; 15:1490472.

PMID: 39660122 PMC: 11628869. DOI: 10.3389/fimmu.2024.1490472.

Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighting the Role of Advanced Practice Providers (Nurse Practitioners and Physician Assistants).

Cochran W, Dioverti M, Langlee J, Barker L, Shedeck A, Toman L Ann Transplant. 2024; 29:e941185.

PMID: 38650316 PMC: 11055468. DOI: 10.12659/AOT.941185.

Mycophenolate Mofetil-Induced Aphthous Stomatitis After Kidney Transplant: A Clinical Case Report.

Almeslet A Cureus. 2024; 15(12):e50811.

PMID: 38249270 PMC: 10797224. DOI: 10.7759/cureus.50811.

References

Fuchinoue S, Ishii Y, Sawada T, Murakami T, Iwadoh K, Sannomiya A . The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction. Transplantation. 2011; 91(8):853-7. DOI: 10.1097/TP.0b013e31820f08e8. View

Gabardi S, Millen P, Hurwitz S, Martin S, Roberts K, Chandraker A . Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation. Clin Transplant. 2012; 26(3):E184-90. DOI: 10.1111/j.1399-0012.2012.01624.x. View

Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C . Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation. 1997; 63(1):39-47. DOI: 10.1097/00007890-199701150-00008. View

Ciancio G, Burke G, Gaynor J, Carreno M, Cirocco R, Mathew J . A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation. 2005; 80(4):457-65. DOI: 10.1097/01.tp.0000165847.05787.08. View

. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation. 1996; 61(7):1029-37. View

Faguer S, Kamar N, Guilbeaud-Frugier C, Fort M, Modesto A, Mari A . Rituximab therapy for acute humoral rejection after kidney transplantation. Transplantation. 2007; 83(9):1277-80. DOI: 10.1097/01.tp.0000261113.30757.d1. View

Wolach O, Bairey O, Lahav M . Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore). 2010; 89(5):308-318. DOI: 10.1097/MD.0b013e3181f2caef. View

Otrock Z, Mahfouz R, Oghlakian G, Salem Z, Bazarbachi A . Rituximab-induced acute thrombocytopenia: a report of two cases. Haematologica. 2005; 90 Suppl:ECR23. View

Trindade E, Maton P, Reding R, De Ville De Goyet J, Otte J, Buts J . Use of granulocyte macrophage colony stimulating factor in children after orthotopic liver transplantation. J Hepatol. 1998; 28(6):1054-7. DOI: 10.1016/s0168-8278(98)80356-5. View

10.

Yang Y, Yu B, Chen Y . Blood disorders typically associated with renal transplantation. Front Cell Dev Biol. 2015; 3:18. PMC: 4365751. DOI: 10.3389/fcell.2015.00018. View

11.

Taylor R, Lindorfer M . Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis. Nat Clin Pract Rheumatol. 2007; 3(2):86-95. DOI: 10.1038/ncprheum0424. View

12.

Mudge D, Atcheson B, Taylor P, Pillans P, Johnson D . Severe toxicity associated with a markedly elevated mycophenolic acid free fraction in a renal transplant recipient. Ther Drug Monit. 2004; 26(4):453-5. DOI: 10.1097/00007691-200408000-00017. View

13.

Tierce J, Porterfield-Baxa J, Petrilla A, Kilburg A, Ferguson R . Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin Transplant. 2005; 19(6):779-84. DOI: 10.1111/j.1399-0012.2005.00421.x. View

14.

Crawford J, Caserta C, Roila F . Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol. 2010; 21 Suppl 5:v248-51. DOI: 10.1093/annonc/mdq195. View

15.

Bodey G, Buckley M, SATHE Y, Freireich E . Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966; 64(2):328-40. DOI: 10.7326/0003-4819-64-2-328. View

16.

Ishida H, Inui M, Furusawa M, Tanabe K . Late-onset neutropenia (LON) after low-dose rituximab treatment in living related kidney transplantation--single-center study. Transpl Immunol. 2013; 28(2-3):93-9. DOI: 10.1016/j.trim.2013.01.003. View

17.

Galutira P, Del Rio M . Understanding renal posttransplantation anemia in the pediatric population. Pediatr Nephrol. 2011; 27(7):1079-85. PMC: 3362719. DOI: 10.1007/s00467-011-2036-1. View

18.

Holdaas H, Midtvedt K, Asberg A . A drug safety evaluation of everolimus in kidney transplantation. Expert Opin Drug Saf. 2012; 11(6):1013-22. DOI: 10.1517/14740338.2012.722993. View

19.

Noel C, Abramowicz D, Durand D, Mourad G, Lang P, Kessler M . Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol. 2009; 20(6):1385-92. PMC: 2689909. DOI: 10.1681/ASN.2008101037. View

20.

Brachemi S, Bollee G . Renal biopsy practice: What is the gold standard?. World J Nephrol. 2014; 3(4):287-94. PMC: 4220363. DOI: 10.5527/wjn.v3.i4.287. View